BRCA1 and neoplasm: Rondinelli et al. (73) performed a gene expression analysis of chromatin modifiers in HR-defective BRCA1/2-deficient tumors and found the enhancer of zeste homolog 2 (EZH2) to score as the top overexpressed chromatin modifier in various tumor types.